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Objective: Recent evidence has highlighted the importance of vitamin D to the development 
of the central nervous system. Some studies have shown an association between maternal 
vitamin D deficiency during pregnancy and offspring Attention-deficit/hyperactivity disorder 
(ADHD) symptoms based on parent- or teacher ratings. There are no previous studies on 
early pregnancy 25-hydroxyvitamin D (25(OH)D) levels and the risk of diagnosed offspring 
ADHD. Our aim was to examine maternal 25(OH)D levels in early pregnancy and offspring 
ADHD. 
Method: In this nationwide population-based case-control study, 1067 ADHD cases born 
between 1998 and 1999 and diagnosed according to the International Classification of 
Diseases and 1067 matched controls, were identified from Finnish registers. Maternal 
25(OH)D levels were measured using quantitative immunoassay from maternal sera, 
collected during the first trimester, and archived in the national biobank. Conditional logistic 
regression was used to examine the association between maternal 25(OH)D and offspring 
ADHD. 
Results: There was a significant association between decreasing log-transformed maternal 
25(OH)D levels and offspring ADHD both in the unadjusted analyses (OR 1.65, 95% CI 
1.33-2.05, P<.001) as well as in the analyses adjusting for matern l socio-economic status 
and age (OR 1.45, 95% CI 1.15-1.81, P=.002). Analyses by quintiles of maternal 25(OH)D 
levels in the lowest versus highest quintile revealed an adjusted odds ratio for offspring 
ADHD of 1.53 (95% CI 1.11-2.12, P=.010). 
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Conclusion: This study demonstrated an association between low maternal 25(OH)D during 
pregnancy and an elevated risk for offspring ADHD.  If replicated in independent samples, 
this finding may have significant public health implications. 


























Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, 
with an estimated worldwide prevalence of approximately 5 %.1 The disorder is characterized 
by symptoms of inattention, hyperactivity and impulsivity, and is associated with significant 
functional impairment. The etiology of ADHD is thought to be multifactorial with a strong 
genetic liability.2 However, environmental risk factors2-5 appear to play a role in the 
development of the disorder.6 
Vitamin D has long been acknowledged for its essential role in bone health and development. 
The discovery that most tissues and cells in the body have a vitamin D receptor has provided 
new insights into its function.7 Evidence is growing of the importance of vitamin D on many 
extra-skeletal functions such as on the immune system, the central nervous system and on 
mental health.8,9 Some studies have shown an association between vitamin D deficiency 
during pregnancy and offspring autism and schizophrenia.10,11 Vitamin D, synthesized in the 
skin and from dietary sources, is metabolized in the liver to 25-hydroxyvitamin D 25(OH)D, 
which is used to determine a patient's vitamin D status.7 
The studies examining the association of maternal 25(OH)D levels during pregnancy or those 
measured at birth among children with ADHD symptoms, have yielded contradictory results. 
Three studies12-14 have shown positive associations between lower matern l 25(OH)D levels 
and ADHD symptoms, while three other studies15-17 have found no association. Among these, 
two studies found a positive finding between maternal vitamin D deficiency in early 
pregnancy and a higher level of ADHD symptoms in offspring based on teacher12 or parent13 
ratings. 
There are only two studies of maternal vitamin D defici ncy and cases diagnosed with 
ADHD.15,16 A Danish study found no association between maternal 25(OH)D measured at 
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gestational week 30 and offspring ADHD.15 A Swedish case-control study also reported no 
association between cord blood 25(OH)D at birth and ADHD.16 These studies are novel and 
potentially important, though there are limitations. First, the previous two studies of vitamin 
D and diagnosed ADHD included small to modest sample sizes (N=2415 and N=20216 ADHD 
cases) that may limit statistical power to show signif cant associations. Second, the 25(OH)D 
measurements were based on samples taken in late pregnancy or at birth in the previous 
studies with diagnosed ADHD cases. The ascertainment of 25(OH)D from maternal serum 
collected during early pregnancy allows for examination of the effects of vitamin D 
deficiency during a period when events including neuronal proliferation and migration are 
taking place.13,18 Third, these previous studies offered limited adjustment for confounders, 
with no information on parental psychiatric diagnoses.  
The present study is the first to examine maternal 25(OH)D levels in early pregnancy and 
diagnosed ADHD cases among the offspring in a large nationwide, population-based birth 
cohort. The study offered availability of information on several potential confounding factors. 
The data were collected from Finland, which is among the northernmost European countries 
with very little sun light exposure during the winter, and prior to 2004, when the national 
recommendation for vitamin D supplementation for pregnant women commenced. The 
consequent vulnerability to vitamin D deficiency allowed for enrichment of the exposure, 
further improving the power to investigate this association. Based on the previous findings on 
early pregnancy vitamin D levels and parent or teach r rated ADHD symptom scores,12,13 we 
hypothesized that low maternal 25(OH)D in early gestation is associated with increased odds 




The Finnish Prenatal study of ADHD is a nested case-control study derived from all singleton 
live births in Finland between 1991 and 2005 (N =870 695) and followed up for ADHD 
diagnosis in the Care Register for Health Care (CRH) until 2011. In the present study, 
maternal vitamin D level assessments utilizing maternal serum samples were performed for 
ADHD cases (F90) and matched controls born between 1998 and 1999 (see “Identification of 
cases and controls” below). 
Nationwide Registers 
The data used in this study were derived from three national registers: the Care Register for 
Health Care (CRHC), the Finnish Medical Birth Register (FMBR), and the Finnish Central 
Population Register (FCPR), which were linked using the personal identity codes. 
The CRHC includes all public and private inpatient diagnoses since January 1, 1967, and 
outpatient diagnoses from specialized services since January 1, 1998. The diagnoses are 
based on the International Classification of Diseases (ICD). The ICD-10 has been used since 
1996,20 ICD-9 from 1987 to 1995,21 and ICD-8 from 1969 to 198622. A previous diagnostic 
validation study of the ADHD diagnoses in the CRHC, which are based on the ICD-criteria 
for hyperkinetic disorder, showed that 88% of the subjects examined met the  DSM-IV 
diagnostic criteria for ADHD.23 The ICD-10 and DSM-IV criteria for hyperkinetic disorder / 
ADHD overlap, but the DSM-IV criteria are generally broader and the ICD-criteria 
stricter.24,25,26 
The FMBR, established in 1987, contains comprehensiv  data on all newborns in Finland 
during the neonatal period up to seven days of age. Data include demographic characteristics, 
reproductive history, maternal health-related behaviors and perinatal events.  
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The FCPR is a digital national archive containing basic demographic information about 
virtually all residents of Finland. The data include name, personal identification number, 
address, citizenship, native language, relatives, and date of birth and death (if applicable). 
Identification of Cases and Controls 
The ADHD cases were identified from the CRHC by using the personal identification code. 
In the present study the ADHD cases included singletons born in Finland between 1998 and 
1999 and registered in the CRHC with the ICD-10 codes of hyperkinetic disorders F90.0, 
F90.1, F90.8, or F90.9 by 2011. 
The controls were singleton offspring born in Finland and without a diagnosis in the CRHC 
of ADHD, conduct disorder (which could possibly be misdiagnosed ADHD), or severe 
intellectual disability. The controls were matched 1:1 to the case subjects on sex, date and 
place of birth. The controls were alive and residing in Finland at the date of diagnosis of the 
matched case. Among the 1320 cases and controls identified, sufficient sera was available for 
1067 case-controls pairs. This study was approved by the ethical committees of the Hospital 
District of Southwest Finland, the data protection authorities at the National Institutes of 
Health and Welfare, and the New York State Psychiatric Institute IRB. 
Description of Biobank 
The Finnish Maternity Cohort (FMC) of the Northern Fi land Biobank Borealis was 
established in 1983 as a nationwide effort of the National Institute for Health and Welfare. 
The FMC consists of approximately 2 million serum specimens collected during the first and 
early second trimester of pregnancy (5th to 95th percentile: months 2–4 of pregnancy) from 
over 950,000 women. The FMC covers virtually all pregnancies in Finland with archived 
prenatal serum specimens drawn for routine screening for congenital infections. Following 
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informed consent, the remaining serum samples (one sample of 1-3 mLs for each pregnancy) 
are stored at -25oC in a protected biorepository at the Northern Finland Biobank Borealis in 
Oulu and are available for scientific research.19 All samples in the FMC can be linked with 
offspring by a unique personal identification code, which has been assigned to each resident 
of Finland since 1971.  
Serum 25(OH)D Measurement 
Maternal 25(OH)D measurements were carried out blind to case/control status. The 
25(OH)D levels were measured in archived maternal serum using a chemiluminescence 
microparticle immunoassay (CMIA) by an Architect i2000SR automatic analyzer (Abbott 
Diagnostics) according to the manufacturer’s instructions. We used the CMIA after 
evaluation of the assay by comparing the Architect i2000 method with high-performance 
liquid chromatography (HPLC). Comparing the 25(OH)D results showed a high correlation 
of 0.922. Reproducibility of the CMIA was high (R=0.98). In addition, analysis of a set of 
commercially available quality control samples (six different samples) showed that the 
resulting levels of 25(OH)D were within the SD range of the reference results. 
Coefficients of variation, derived from repeated quality control samples included in the assay 
with the study samples, were calculated.  In control samples with “high” 25(OH)D levels 
(>100 nmol/L), the coefficient of variation (CV) were 3.2%, in samples with “medium” 
25(OH)D levels (~80 nmol/L), the CV was 3.1%, and with “low” 25(OH)D levels (<40 
nmol/L), the CV was 3.6%. In blinded quality control pairs in which 25(OH)D levels were 




A number of potential confounding factors suggested as having an association with offspring 
ADHD and maternal vitamin D levels were considered for inclusion in the analyses.3,4,27-36 
We obtained information on the number of previous births, maternal socioeconomic status 
(SES), maternal age, self-reported smoking during pre nancy, gestational age (GA) and 
weight for gestational age (WGA, based on national sex-specific growth curves)37 from the 
FMBR. The maternal SES categories were existing occupation-based national classifications 
that are used in the FMBR: upper white collar workers, lower white collar workers, blue 
collar workers and others (e.g. students and housewives) or missing (if the data was not 
available). Information on maternal and paternal psychiatric diagnoses, ADHD diagnoses and 
maternal diagnoses of substance use disorder, were obtained from the CRHC. Information on 
maternal immigrant background was obtained from the FCPR and was included because 
certain ethnic minorities have an elevated risk for vitamin D deficiency during pregnancy31 
and an increased likelihood of offspring ADHD diagnosis27. Information on gestational week 
and season of blood draw was obtained from the FMC. The seasons of blood collection were 
defined as: winter (December to February), spring (March to May), summer (June to August) 
and fall (September to November). As smokers are known to have lower 25(OH)D levels33 
and self-reported smoking is underreported,29 we also included maternal cotinine, a 
biomarker of nicotine, in the covariate testing. Maternal cotinine levels were measured using 
quantitative immunoassays; a cotinine level of 20 ng/ml was used as a cut-point to define 
biomarker-based smoking status.29 A more detailed description of all covariates are pr sented 
in Tables 1 and 2. 
Statistical analysis 
We first examined the association of ADHD and maternal 25(OH)D defined as a continuous 
variable. Due to the skewed distribution, 25(OH)D was log-transformed before analysis in 
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order to achieve a normal distribution. Second, we examined maternal 25(OH)D categorized 
into quintiles.  The cut-points for the quintiles of maternal 25(OH)D levels were based on the 
distribution in the control group. We hypothesized that a significant association would be 
observed for maternal 25(OH)D classified in the lowest quintile compared with the reference 
group, which was defined as the highest quintile. In addition, we examined maternal 
25(OH)D as a three-class categorical variable based on clinical categories: deficient 
(25(OH)D<30 nmol/L), insufficient (25(OH)D 30-49.9 nmol/L) and sufficient maternal 
vitamin D levels (25(OH)D>50 nmol/L), where the sufficient category was used as the 
reference group. 
Categorically defined potential confounders were tested with Student’s t and F-tests for the 
association with log-transformed maternal 25(OH)D among controls. For continuous 
potential confounders we used linear regression to test for the association with maternal 
25(OH)D among controls. Conditional logistic regression for matched sets was used to test 
for the association between potential confounders and ADHD. In accord with the extant 
epidemiologic literature, covariates were considered as potential confounders and were 
included in the adjusted regression models if they w re associated with both the exposure and 
the outcome at P<0.10.38 We also tested the distribution of the covariates b tween the 1067 
cases with available sera and the 253 cases lacking sera and thus excluded from the study. 
Point and interval estimates of odds ratios were obtained by fitting conditional logistic 
regression models for matched pairs. Statistical significance was based on P<0.05.  All the 
statistical analyses were performed with SAS software (SAS 9.4, SAS Institute, Cary, N.C.). 
RESULTS 
The mean age at ADHD diagnosis was 7.3 years (SD: 1.9; range: 2-13.7 years). The median 
maternal 25(OH)D level among cases was 29.2 nmol/L (range: 8.9-115.6 nmol/L, Q1= 21.5 
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nmol/L, Q3=41.7 nmol/L) and 32.2 nmol/L (range: 7.5-132.5 nmol/L, Q1=23.2 nmol/L, 
Q3=45.4 nmol/L) among controls. The mean gestational week of maternal blood draw was 
10.7 (SD: 3.7) for cases and 10.6 (SD: 3.1) for controls. The gender distribution was 85.5 % 
male and 14.5% female in cases and in controls. The distribution of maternal 25(OH)D by 
case-control status in quintiles is presented in Figure 1. 
Among the covariates, maternal age, SES, self-report d smoking, psychopathology, 
substance abuse, ADHD diagnosis, immigrant status, number of previous births, and cotinine 
levels; paternal psychopathology and ADHD diagnosis; and offspring GA and WGA were 
associated with offspring ADHD with P<0.1 (Table 1). Maternal age, SES and season of 
blood collection were associated with maternal 25(OH)D level with P<0.1 (Table 2). 
Maternal SES and age were associated with both offspring ADHD and maternal 25(OH)D 
level, and were thus adjusted for in the multivariate nalyses.  
The season of blood collection did not differ between the cases and the controls (P=.86). The 
mean gestational week of maternal blood draw did not differ between the cases and the 
controls (P=.54). The cases and the controls were originally also matched on the date (and 
place) of birth hindering any potential effect of sea on. 
The distribution of the covariates did not differ between the 1067 included cases and the 253 
without available sera. (see Table S1, available onine)  
As shown in Table 3, there was a significant association between decreasing log-transformed 
maternal 25(OH)D levels and increasing risk of offspring ADHD both in the unadjusted (OR 
1.65, 95% CI 1.33-2.05, P<.001) and adjusted analyses (OR 1.45, 95% CI 1.15-81, 
P=.002).  To test for possible mediation by WGA or maternal cotinine levels, or for 
confounding by maternal psychiatric history, we ran additional analyses with WGA, maternal 
psychiatric history and maternal biomarker-based smoking-status added to the adjusted 
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model. The associations remained significant in these analyses (see Table 3).  Furthermore, 
an additional analysis adjusting for maternal immigrant background (mother born / not born 
in Finland) also did not change the results (OR 1.44, 95% CI 1.14-1.81, P=.002). For further 
reassurance, we ran additional analyses adjusting also for the remaining covariates associated 
with offspring ADHD and the results remained significant in all additional analyses (see 
Table S2, available online) 
Given the established differences in the risk of ADHD by sex, we tested for sex-by-25(OH)D 
interaction and found no evidence of effect modification by sex on the relationship between 
maternal 25(OH)D and ADHD (P=.84). In addition, we tested for a possible effect of the age 
at diagnosis and found no interaction between the age at ADHD diagnosis and maternal 
25(OH)D levels (P=.78). 
The distribution of maternal 25(OH)D in quintiles by case-control status is presented in Table 
4. The odds ratio for ADHD among offspring of mothers in the lowest vitamin D quintile 
compared to the highest quintile was 1.83 (95% CI 1.34-2.51, P<.001) in the unadjusted 
model and 1.53 (95% CI 1.11-2.12, P=.010) in the adjusted model (Table 4). In the additional 
analyses when maternal 25(OH)D levels were classified nto three clinical categories, 
maternal vitamin D deficiency (25(OH)D<30 nmol/L) was associated with offspring ADHD 
in the unadjusted analyses (OR 1.51, 95 % CI 1.15-199, P=.003) as well as when adjusted 
for maternal age and SES (OR 1.34, 95% CI 1.008-1.7 P= .044). (See Table S3, available 
online) 
DISCUSSION 
The present study is the first to demonstrate an association between low maternal 25(OH)D 
level in early to mid-pregnancy and an elevated risk for diagnosed ADHD in the offspring in 
a large nationwide, population-based sample. The association was observed both when 
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vitamin D was analyzed as a linear and as a categorical variable. These findings are the 
strongest evidence to date of a link between developmental vitamin D deficiency and 
offspring ADHD. Our results are in accord with two studies showing associations between 
lower maternal 25(OH)D levels in early pregnancy and higher levels of teacher12 or parent13 
rated offspring ADHD symptoms. 
There are biologically plausible explanations for the association between developmental 
vitamin D deficiency and an increased risk of offspring ADHD. Early pregnancy is a critical 
period for fetal brain development, which is a complex process influenced by the individual’s 
genotype and the in utero environment.11,39 Low vitamin D levels result from inadequate sun 
exposure, low vitamin D intake from diet as well as physiological risk factors such as obesity 
and skin color.35 The present findings suggest that insufficient in utero vitamin D may 
adversely influence fetal programming and expose the offspring to a suboptimal environment 
resulting in possible ADHD. Vitamin D receptors areexpressed in the brain, and research has 
shown that vitamin D affects brain function through regulation of calcium signaling, 
neurotrophic and neuroprotective actions, neuronal differentiation, maturation and 
growth.8,9,40 
The present findings are supported by observations fr m animal studies, which have shown 
that developmental vitamin D deficiency is associated with a range of persistent 
neurochemical and behavioral outcomes.8 Depleting vitamin D leads to changes in multiple 
neurotransmitters in the brains of newborn rats.41 One finding among vitamin D deficient rats 
has been altered dopamine signaling.8 Early vitamin D deficiency may enhance 
hyperlocomotion and increase activity among rats.42 These mechanisms have previously been 
linked to schizophrenia and autism, but may well have relevance to ADHD as well, notably 
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alterations in ontogeny of dopamine systems, novelty-induced hyperlocomotion, and 
disrupted latent inhibition, indicative of abnormal attentional processing.43,44  
Despite the marked reduction in the prevalence of many nutritional deficiencies in the 
developed world, vitamin D deficiency still remains common, and therefore the present study 
could have significant public health implications.7,45 Vitamin D deficiency is especially 
prevalent among pregnant women, and this results in ow vitamin D levels in the fetus and 
offspring in early life.46 A recent meta-analysis concluded that higher circulating prenatal 
25(OH)D levels may have positive effects on the offspring’s neurodevelopment and reduce 
the risk of ADHD and autism-related traits.47 Interestingly, another recent meta-analysis 
showed that 25(OH)D serum concentrations were also lower among children and adolescents 
with ADHD.48 Although a cconsensus has not been reached regardin  the criteria of 
sufficient concentrations of 25(OH)D for pregnant women, the Institute of Medicine, in their 
updated report from 2011,49 suggested that 25(OH)D concentrations of at least 30 nmol/L 
would prevent deficiency with respect to bone health nd that 50 nmol/L would be sufficient 
in most people.50 The maternal 25(OH)D concentrations in our study were low with a median 
value of 29.2 nmol/L among mothers of cases and 32.2 nmol/L among mothers of controls. 
Of note, in the lowest quintile, which as reported above showed the strongest association with 
ADHD, the maternal 25(OH)D concentrations were 7.5 to 21.9 nmol/ L. The overall low 
vitamin D concentrations could be attributed to the fact that maternal sera were collected 
from pregnancies between 1998 and 1999, long before vitamin D supplementation 
recommendations for pregnant women in Finland began in 2004. In addition, Finland is 
situated in Northern Europe in a far northern latitude (between 60° and 70°N) with long 




The strengths of the present study include the large nationwide sample, assessment of 
maternal 25(OH)D concentrations based on prospectively collected sera in the first and early 
second trimesters, and control for a wide range of potential confounders including date of 
birth, place of birth, maternal psychiatric history, immigration background, child’s weight for 
gestational age and prenatal nicotine exposure. 
There are several limitations that must be considered. First, the ADHD subjects in this study 
included only those who had been referred to specialized services and likely represent the 
more severe ADHD cases. Of note, the cases were diagnosed with the ICD-criteria for 
hyperkinetic disorder that are generally stricter than the DSM-criteria for ADHD.24,25 The 
validity of the ADHD diagnoses in the CRHC have been valuated  previously with 88% of 
the register-diagnosed patients examined by telephone interviews meeting the DSM-IV 
criteria for ADHD.23 Second, the number of parents diagnosed with ADHD was low, possibly 
because ADHD was not a widely used diagnosis in Finland in the parental generation. Third, 
we were able to assess maternal 25(OH)D at only one time point of pregnancy. However, it is 
likely that the mother’s 25(OH)D concentration was similar throughout pregnancy.36 Fourth, 
it is possible that unmeasured factors confounded th  association of vitamin D deficiency and 
ADHD; unfortunately, maternal body mass index data were not available. Furthermore, lower 
maternal 25(OH)D could be an indicator of other prenatal risk factors such as a poorer diet 
(i.e. containing less beneficial fatty acids) or lack of compliance with general health 
recommendations for prenatal care. However, our adjusted model did include maternal SES, 
maternal age, and maternal psychiatric history, which are related to those factors. 
Furthermore, our additional mediation analyses by child’s weight for gestational age and 
maternal cotinine levels did not change the results. Fifth, we did not have data on maternal 
medications with possible effects on maternal vitamn D levels. Sixth, the generalizability of 
the findings to various ethnic groups with differing vulnerability to vitamin D deficiency is 
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low due to the low number of immigrant mothers. Future studies with ethnically more diverse 
samples are needed. 
This is the first population-based study to demonstrate an association between low maternal 
vitamin D level in early to mid-pregnancy and an increased risk for offspring ADHD 
diagnosis. If these findings are replicated, they may have public health implications for 
vitamin D supplementation and perhaps changing life-style behaviors during pregnancy to 




1. Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and young people: 
prevalence, care pathways, and service provision. La cet Psychiatry. 2018;5(2):175-186. 
doi:10.1016/S2215-0366(17)30167-0 
2. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 
2016;387(10024):1240-1250. doi:10.1016/S0140-6736(15)00238-X 
3. Sucksdorff M, Lehtonen L, Chudal R, et al. Preterm Birth and Poor Fetal Growth as Risk 
Factors of Attention-Deficit/ Hyperactivity Disorder. Pediatrics. 2015;136(3):e599-608. 
doi:10.1542/peds.2015-1043 
4. Chudal R, Joelsson P, Gyllenberg D, et al. Parental age and the risk of attention-
deficit/hyperactivity disorder: a nationwide, population-based cohort study. J Am Acad 
Child Adolesc Psychiatry. 2015;54(6):487-494.e1. doi:10.1016/j.jaac.2015.03.01  
5. Silva D, Colvin L, Hagemann E, Bower C. Environmental risk factors by gender 
associated with attention-deficit/hyperactivity disorder. Pediatrics. 2014;133(1):e14-22. 
doi:10.1542/peds.2013-1434 
6. Thapar A, Cooper M, Eyre O, Langley K. What have we learnt about the causes of 
ADHD? J Child Psychol Psychiatry. 2013;54(1):3-16. doi:10.1111/j.1469-
7610.2012.02611.x 
7. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281. doi: 
10.1056/NEJMra070553 
8. Groves NJ, McGrath JJ, Burne TH. Vitamin D as a neurosteroid affecting the developing 




9. Kesby JP, Eyles DW, Burne TH, McGrath JJ. The effects of vitamin D on brain 
development and adult brain function. Mol Cell Endocrinol. 2011;347(1-2):121-127. 
doi:10.1016/j.mce.2011.05.014 
10. Vinkhuyzen AAE, Eyles DW, Burne THJ, et al. Gestational vitamin D deficiency and 
autism spectrum disorder. BJPsych Open. 2017;3(2):85-90. 
doi:10.1192/bjpo.bp.116.004077 
11. Eyles DW, Trzaskowski M, Vinkhuyzen AAE, et al. The association between neonatal 
vitamin D status and risk of schizophrenia. Sci Rep. 2018;8(1):17692. 
doi:10.1038/s41598-018-35418-z 
12. Morales E, Julvez J, Torrent M, et al. Vitamin D in Pregnancy and Attention Deficit 
Hyperactivity Disorder-like Symptoms in Childhood. Epidemiology. 2015;26(4):458-
465. doi:10.1097/EDE.0000000000000292. 
13. Daraki V, Roumeliotaki T, Koutra K, et al. High maternal vitamin D levels in early 
pregnancy may protect against behavioral difficulties at preschool age: the Rhea mother-
child cohort, Crete, Greece. Eur Child Adolesc Psychiatry. 2018;27(1):79-88. 
doi:10.1007/s00787-017-1023-x 
14. Mossin MH, Aaby JB, Dalgård C, Lykkedegn S, Christesen HT, Bilenberg N. Inverse 
associations between cord vitamin D and attention deficit hyperactivity disorder 
symptoms: A child cohort study. Aust N Z J Psychiatry. 2017;51(7):703-710. 
doi:10.1177/0004867416670013 
15. Strøm M, Halldorsson TI, Hansen S, et al. Vitamin D measured in maternal serum and 
offspring neurodevelopmental outcomes: a prospectiv study with long-term follow-up. 
Ann Nutr Metab. 2014;64(3-4):254-261. doi:10.1159/000365030 
18 
 
16. Gustafsson P, Rylander L, Lindh CH, et al. Vitamin D Status at Birth and Future Risk of 
Attention Deficit/Hyperactivity Disorder (ADHD). PLoS One. 2015;10(10):e0140164. 
doi:10.1371/journal.pone.0140164 
17. Keim SA, Bodnar LM, Klebanoff MA. Maternal and cord blood 25(OH)-vitamin D 
concentrations in relation to child development andbehaviour. Paediatr Perinat 
Epidemiol. 2014;28(5):434-444. doi:10.1111/ppe.12135 
18. Wang R, Dai G, Takahashi E. High Resolution MRI Reveals Detailed Layer Structures 
in Early Human Fetal Stages: In Vitro Study with Histologic Correlation. Front 
Neuroanat. 2015;9:150. doi:10.3389/fnana.2015.00150 
19. Gissler M, Surcel HM. Combining health register data nd biobank data. Stat J IAOS. 
2012;28(1-2):53-58. doi:10.3233/SJI-2012-0744 
20. World Health Organization (WHO). International classification of diseases, tenth 
revision (ICD-10). Geneva, Switzerland: World Health Organization; 1992. 
21. World Health Organization (WHO). International classification of diseases, ninth 
revision (ICD-9). Geneva, Switzerland: World Health Organization; 1977. 
22. World Health Organization (WHO). International Classification of Diseases, Eighth 
Revision. Geneva, Switzerland: World Health Organization; 1967. 
23. Joelsson P, Chudal R, Gyllenberg D, et al. Demographic Characteristics and Psychiatric 
Comorbidity of Children and Adolescents Diagnosed with ADHD in Specialized 
Healthcare. Child Psychiatry Hum Dev. 2016;47(4):574-582. doi:10.1007/s10578-015-
0591-6 
24. Tripp G, Luk SL, Schaughency EA, Singh R. DSM-IV and ICD-10: a comparison of the 




25. Lahey BB, Pelham WE, Chronis A, et al. Predictive validity of ICD-10 hyperkinetic 
disorder relative to DSM-IV attention-deficit/hyperactivity disorder among younger 
children. J Child Psychol Psychiatry. 2006;47(5):472-479. doi:10.1111/j.1469-
7610.2005.01590.x 
26. Santosh, P. J., Taylor, E., Swanson, J. et al. Refining the diagnoses of inattention and 
overactivity syndromes: A reanalysis of the Multimodal Treatment study of attention 
deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic 
disorder. Clinical Neuroscience Research, 5(5-6), 307-314 
27. Lehti V, Chudal R, Suominen A, Gissler M, Sourander A. Association between 
immigrant background and ADHD: a nationwide population-based case-control study. J 
Child Psychol Psychiatry. 2016;57(8):967-975. doi:10.1111/jcpp.12570 
28. Joelsson P, Chudal R, Uotila J, et al. Parental psychopathology and offspring attention-
deficit/hyperactivity disorder in a nationwide sample. J Psychiatr Res. 2017;94:124-130. 
doi:10.1016/j.jpsychires.2017.07.004 
29. Sourander A, Sucksdorff M, Chudal R, et al. Prenatal Cotinine Levels and ADHD 
Among Offspring. Pediatrics. 2019;143(3):e20183144. doi:10.1542/peds.2018-3144 
30. Miliku K, Vinkhuyzen A, Blanken LM, et al. Maternal vitamin D concentrations during 
pregnancy, fetal growth patterns, and risks of adverse birth outcomes. Am J Clin Nutr. 
2016;103(6):1514-1522. doi:10.3945/ajcn.115.123752  
31. Eggemoen ÅR, Falk RS, Knutsen KV, et al. Vitamin D deficiency and supplementation 
in pregnancy in a multiethnic population-based cohort. BMC Pregnancy Childbirth. 
2016;16:7. doi:10.1186/s12884-016-0796-0 
32. Qin LL, Lu FG, Yang SH, Xu HL, Luo BA. Does Maternal Vitamin D Deficiency 




33. Lokki AI, Heikkinen-Eloranta J, Öhman H, Heinonen S, Surcel HM, Nielsen HS. 
Smoking during pregnancy reduces vitamin D levels in a Finnish birth register cohort 
[Epub ahead of print]. Public Health Nutr. 2019:1-5. doi: 10.1017/S1368980018003932 
34. Manavi KR, Alston-Mills BP, Thompson MP, Allen JC. Effect of serum cotinine on 
vitamin D serum concentrations among american femals with different ethnic 
backgrounds. Anticancer Res. 2015;35(2):1211-1218. 
35. Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment 
and prevention. Rev Endocr Metab Disord. 2017;18(2):153-165. doi:10.1007/s11154-
017-9424-1 
36. Hauta-Alus HH, Holmlund-Suila EM, Rita HJ, et al. Season, dietary factors, and physical 
activity modify 25-hydroxyvitamin D concentration during pregnancy. Eur J Nutr. 
2018;57(4):1369-1379. doi:10.1007/s00394-017-1417-z 
37. Sankilampi U, Hannila ML, Saari A, Gissler M, Dunkel L. New population-based 
references for birth weight, length, and head circumference in singletons and twins from 
23 to 43 gestation weeks. Ann Med. 2013;45(5-6):446- 54. 
doi:10.3109/07853890.2013.803739 
38. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, PA: 
Lippincott-Raven; 1998 
39. Freedman R, Hunter SK, Hoffman MC. Prenatal Primary Prevention of Mental Illness by 
Micronutrient Supplements in Pregnancy. Am J Psychiatry. 2018;175(7):607-619. 
doi:10.1176/appi.ajp.2018.17070836 
40. Cui X, Pelekanos M, Liu PY, Burne TH, McGrath JJ, Eyles DW. The vitamin D receptor 
in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat 
midbrain. Neuroscience. 2013;236:77-87. doi:10.1016/j.neuroscience.2013.01.035 
21 
 
41. Kesby JP, Turner KM, Alexander S, Eyles DW, McGrath JJ, Burne THJ. Developmental 
vitamin D deficiency alters multiple neurotransmitter systems in the neonatal rat brain. 
Int J Dev Neurosci. 2017;62:1-7. doi:10.1016/j.ijdevneu.2017.07.002 
42. Burne TH, Becker A, Brown J, Eyles DW, Mackay-Sim A, McGrath JJ. Transient 
prenatal Vitamin D deficiency is associated with hyperlocomotion in adult rats. Behav 
Brain Res. 2004;154(2):549-555. doi:10.1016/j.bbr.2004.03.02 
43. Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain 
function and the links between low levels of vitamin D and neuropsychiatric disease. 
Front Neuroendocrinol. 201;34(1):47-64. doi:10.1016/j.yfrne.2012.07.001 
44. Berridge MJ. Vitamin D deficiency: infertility and neurodevelopmental diseases 
(attention deficit hyperactivity disorder, autism, and schizophrenia). Am J Physiol Cell 
Physiol. 2018;314(2):C135-C151. doi:10.1152/ajpcell.00188.2017 
45. Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US 
adults. Nutr Res. 2011;31(1):48-54. doi:10.1016/j.nutres.2010.12.001 
46. Lee JM, Smith JR, Philipp BL, Chen TC, Mathieu J, Holick MF. Vitamin D deficiency 
in a healthy group of mothers and newborn infants. Clin Pediatr (Phila). 2007;46(1):42-
44. doi:10.1177/0009922806289311 
47. García-Serna AM, Morales E. Neurodevelopmental effects of prenatal vitamin D in 
humans: systematic review and meta-analysis. Mol Psychiatry. 2019 Jan 29. doi: 
10.1038/s41380-019-0357-9 
48. Kotsi E, Kotsi E, Perrea DN. Vitamin D levels in children and adolescents with 
attention-deficit hyperactivity disorder (ADHD): a meta-analysis. Atten Defic Hyperact 
Disord. 2019 Sep;11(3):221-232. doi: 10.1007/s12402-018-0276-7. Epub 2018 Oct 26. 
22 
 
49. Ross AC, Manson JE, Abrams SA, et al. The 2011 Dietary Reference Intakes for 
Calcium and Vitamin D: what dietetics practitioners need to know. J Am Diet Assoc. 
2011;111(4):524-527. doi:10.1016/j.jada.2011.01.004 
50. Dodds L, Woolcott CG, Weiler H, et al. Vitamin D Status and Gestational Diabetes: 



















Figure 1. Distribution of Maternal 25(OH)D Levels by Offspring's Attention-
Deficit/Hyperactivity Disorder Case-Control Status 




















Table 1. Covariates in Relation to Attention-Deficit/Hyperactivity Disorder (ADHD) 
 
Note: Boldface type indicates. SE = standard error; SES = socioeconomic status.  
a Maternal smoking missing for 27 cases and 32 controls 
b International Classification of Diseases, Revision 8 (ICD-8) (291-308), ICD-9 (291-316) or 
ICD-10 (F10-99), excluding mental retardation (F70-79), ADHD diagnosis (ICD-10: F90.X 
or ICD-9: 314.X) and substance abuse diagnosis (ICD-8: 291, 303, 304, ICD-9: 291, 292, 
303, 304, 305 or ICD-10: F10-19) 
c ICD-8 (291, 303, 304), ICD-9 (291, 292, 303, 304, 305) or ICD-10 (F10-19) 
d ICD-10: F90.X or ICD-9: 314.X 
e ICD-8 (291-308), ICD-9 (291-316) or ICD-10 (F10-99), excluding mental retardation (F70-
79) and ADHD diagnosis (ICD-10: F90.X or ICD-9: 314.X) 
f Paternal psychopathology and paternal ADHD diagnosis missing for 28 cases and 7 controls 
g Gestational age missing for 4 cases and 5 controls 





Number of previous 
births 
0 505 (47.3%) 419 (39.3%) .002 
≥1 562 (52.7%) 648 (60.7%)  
Maternal smokinga No 731 (70.3) 900 (87.0) <.001 
 Yes 309 (29.7) 135 (13.0)  
History of maternal  
psychopathologyb 
No 794 (74.4%) 940 (88·1%) <.001 
Yes 273 (25.6) 127 (11.9)  
History of maternal 
substance abusec 
No 1010 (94.7%) 1052 (98.6%) <.001 
Yes 57 (5.3%) 15 (1.4%)  
History of maternal 
ADHD diagnosisd 
No  1060 (99.3%) 1066 (99.9%) .07 
Yes 7 (0.7%) 1 (0.1%)  
History of paternal 
psychopathologye,f 
No 783 (75.4%) 920 (86.8%) <.001 
Yes 256 (24.6%) 140 (13.2%)  
History of paternal 
ADHD diagnosisd,f 
No 1030 (99.1%) 1058 (99.8%) 0.03 
Yes 9 (0.9%) 2 (0.2%)  
Gestational age (weeks)g 
 
<37 101 (9.5%) 42 (4.0 %) <.001 
≥37 962 (90.5%) 1020 (96.1%)  
Maternal immigrant 
status 
Born in Finland 1043 (97.8%) 1059 (99.3%) 0.004 
Not born in Finland 24 (2.3%) 8 (0.8%)  
Maternal cotinine <20 770 (72.2%) 927 (87.0 %) <.001 
(ng/ml) ≥20 297 (27.84) 139 (13.0%)  
Maternal SES Upper white collar 73 (6·8%) 143 (13.4%) <.001 
 Lower white collar 466 (43.7%) 426 (39.9%)  
 Blue collar 219 (20.5%) 191 (17.9%)  
 Others 213 (20.0%) 165 (15.5%)  
 Missing 136 (12.8%) 102 (9.6%)  
Birth weight for 
gestational ageh 
SGA ( < - 2SD) 
AGA ( -2SD to +2SD) 








Season of blood 
collection 
Winter (Dec-Feb) 298 (27.9%) 288 (27.0%) 0.86 
Spring (Mar-May) 291 (27.3%) 307 (28.8%)  
Summer (Jun-Aug) 228 (21.4%) 220 (20.6%)  
 Autumn (Sep-Nov) 250 (23.4%) 252 (23.6%)  
  Mean (SE) Mean (SE)  
Maternal age (years)  27.9 (0.18) 29.5 (0.16) <.001 
Gestational week of blood draw 10.7 (0.11) 10.6 (0.10) .54 
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Note: ADHD = attention-deficit/hyperactivity disorder; ICD = International Classification of 
Diseases. SE = standard error; SES = socioeconomic status.  
 a Maternal smoking missing for 27 cases and 32 controls 
b ICD-8 (291-308), ICD-9 (291-316) or ICD-10 (F10-99), excluding intellectual disability 
(F70-79), ADHD diagnosis (ICD-10: F90.X or ICD-9: 314.X)  and substance abuse diagnosis 
(ICD-8: 291, 303, 304, ICD-9: 291, 292, 303,304,305 or ICD-10: F10-19) 
c ICD-8 (291, 303, 304), ICD-9 (291, 292, 303,304,305) or ICD-10 (F10-19) 
d ICD-10: F90.X or ICD-9: 314.X 
 log-transformed maternal 25(OH)D 
  Mean SD p 
Number of previous 
births 
0 3.46 0.46 .18 
≥1 3.50 0.46  







History of maternal  
psychopathology b
No 3.49 0.46 .18 
Yes 3.43 0.44  
History of maternal 
substance abusec 
No 3.49 0.46 .51 
Yes 3.41 0.38  
History of maternal 
ADHD diagnosisd 
No  3.48 0.46 .32 
Yes 3.03 -e  
History of  paternal  
psychopathologyf,g 
No 3.49 0.45 .23 
Yes 3.44 0.49  
History of paternal 
ADHD diagnosisd,g 
No 3.48 0.46 .83 
Yes 3.41 0.38  
Gestational age (weeks)h <37 3.46 0.47 .66 
≥37 3.49 0.46  
Maternal immigrant 
status 
Born in Finland 3.48 0.46 .57 
Not born in Finland 3.58 0.51  
Maternal cotinine <20 3.48 0.46 0.87 
ng/ml ≥20 3.48 0.46  
 least squares means SE  
Maternal SES Upper white collar 3.54 0.04 .016 
 Lower white collar 3.50 0.02  
 Blue collar 3.51 0.03  
 Others 3.42 0.04  
 Missing 3.38 0.05  
Weight for gestational 
agei 
SGA ( < - 2SD) 
AGA ( -2SD to +2SD) 








Season of blood 
collection 
Winter (Dec-Feb) 3.32 0.02 <.001 
Spring (Mar-May) 3.28 0.02  
 Summer (Jun-Aug) 3.84 0.03  
 Autumn (Sep-Nov) 3.61 0.03  
parameter estimatej SE p  
Maternal age (years)  1.15 0.35 .001 
Gestational week of blood draw -0.31 0.21 .13 
27 
 
f ICD-8 (291-308), ICD-9 (291-316) or ICD-10 (F10-99), excluding intellectual disability 
(F70-79) and ADHD diagnosis (ICD-10: F90.X or ICD-9: 314.X)  
g Paternal psychopathology and paternal ADHD diagnosis missing for 7 controls 
h Gestational age missing for 5 controls, i Birth weight for gestational age missing for 5 
controls 
e only one observation,  














Note: OR = odds ratio; SES = socioeconomic status.  
a For one unit decrease, continuous model 
b Adjusted for maternal SES and maternal age 
c Adjusted for maternal SES, maternal age and maternal psychiatric history (International Classification of Diseases, Revision 8 [ICD-8] (291-
308), ICD-9 (291-316) or ICD-10 (F10-99), excluding mental retardation (F70-79), ADHD diagnosis (ICD-10: F90.X or ICD-9: 314.X) and 
substance abuse diagnosis (ICD-8: 291, 303, 304, ICD-9: 291, 292, 303,304,305 or ICD-10: F10-19) 
d Adjusted for maternal SES, maternal age and child’s weight for gestational age 
e Adjusted for maternal SES, maternal age and maternal cotinine (<20 or ≥20 ng/ml) 
 
 Cases N= 1067 Controls N=1067 
 Median (interquartile range) Median (interquartile range) 
Maternal 25(OH)D level 
(nmol/L) 
29.20 (21.47–41.68) 32.20 (23.21–45.43) 
 Association with maternal serum 25(OH)D level 
Log-transformed analysisa OR 95% CI p 
Unadjusted 1.65 1.33-2.05 <.001 
Adjusted model Ab 1.45 1.15-1.81 .002 
Adjusted model Bc 1.40 1.11-1.77 .005 
Adjusted model Cd 1.46 1.16-1.83 .001 





































Unadjusted OR  
(95% CI) 
P-Value Adjusteda OR  
(95% CI) 
P-Value 
0-19% 7.5–21.9 277 210 1.83 (1.34-2.51) <.001 1.53 (1.11-2.12) .010 
20%-39% 22.0–27.6 213 208 1.36 (1.01-1.89) .046 1.30 (0.94-1.79) .11 
40%-59% 27.7–36.4 221 221 1.30 (0.97-1.76) .08 1.21 (0.89-1.65) .23 
60%-79% 36.5–49.4 172 214 1.00 (0.75-1.33) >.99 0.99 (0.73-1.33) .92 
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